Market Overview: The global market size for digital dose inhalers reached USD 2.45 Billion in 2022 and is projected to grow to USD 5.8 Billion by 2032, with a robust compound annual growth rate (CAGR) of 10% during the forecast period. Key drivers of this growth include the increasing prevalence of respiratory illnesses, a growing demand for digital technology in healthcare, and the need for personalized and efficient treatment options.
Factors Driving Market Growth: The demand for digital dose inhalers has surged due to the rising incidence of respiratory conditions like asthma, COPD, and cystic fibrosis. The World Health Organization (WHO) estimates that the global number of asthma sufferers will reach 400 million by 2025. COPD, causing over 3 million deaths annually, stands as the third leading cause of death globally.
Challenges and Restraints: Despite the promising growth, the high cost of digital dose inhalers poses a significant challenge to market expansion. Moreover, a lack of awareness among both medical professionals and patients about digital dose inhalers could impede revenue growth.
Get a sample copy of the Digital Dose Inhaler Market report: https://www.reportsanddata.com/download-free-sample/6980
Key Takeaways:
Product Type Outlook: The market is segmented into smart inhalers and sensor-based inhalers. In 2023, smart inhalers are expected to dominate the market, offering features such as connectivity to smartphones or tablets via Bluetooth. The rise of respiratory illnesses, coupled with advancements in technologies like the Internet of Things (IoT) and artificial intelligence (AI), is driving the demand for smart inhalers.
Sensor-based inhalers, with the ability to detect breathing patterns and provide inhalation instructions, are projected to exhibit a higher revenue CAGR. These inhalers, equipped with sophisticated sensors like accelerometers and gyroscopes, are expected to gain traction, especially with the increasing prevalence of respiratory disorders.
Application Outlook: Application segments include asthma, COPD, and others. The asthma segment is anticipated to dominate the market in 2022, given the significant global prevalence of asthma, estimated at 235 million sufferers. The adoption of cutting-edge technologies like IoT and AI is expected to further fuel the expansion of the asthma segment.
The COPD market category is also poised to contribute substantially to revenue share, driven by the high incidence of COPD globally, particularly linked to smoking. Other respiratory disorders, such as cystic fibrosis and bronchitis, fall under the “Others” category, and their prevalence is expected to drive demand for digital dose inhalers.
Regional Outlook: North America is expected to lead the global market, owing to the high prevalence of respiratory disorders and supportive government initiatives. In the region, FDA approvals for digital inhalers, such as ProAir Digihaler, RespiClick, and ProAir HFA, are expected to expedite market growth.
Europe is anticipated to be the second-largest market, driven by the rising frequency of respiratory disorders, a developed healthcare infrastructure, and favorable government regulations. Recent approvals from the European Medicines Agency for digital inhalers like ProAir Digihaler and Enerzair Breezhaler are expected to further boost market expansion.
Competitive Landscape: The global digital dose inhaler market is witnessing steady growth, driven by factors such as the rising prevalence of respiratory diseases, increasing demand for technologically advanced inhalation devices, and growing awareness among patients and healthcare professionals regarding the benefits of digital dose inhalers. The market is highly competitive, with several established players competing for market share.
Major players in the digital dose inhaler market include GlaxoSmithKline plc, Boehringer Ingelheim GmbH, AstraZeneca, Merck & Co. Inc, Teva Pharmaceutical Industries Ltd, OPKO Health Inc, Adherium Limited, Propeller Health, 3M, and Philips Respironics.
Strategic Developments and New Product Launches:
- In 2021, GlaxoSmithKline collaborated with Apple Inc. to develop an app-enabled digital inhaler for asthma and COPD treatment.
- Boehringer Ingelheim launched the Respimat Smart digital inhaler in 2020, connecting to a mobile app for tracking inhaler usage and providing reminders.
- AstraZeneca introduced the Digihaler digital inhaler in 2020, utilizing sensors for tracking inhaler usage and offering feedback on technique and disease management.
New Product Launches:
- GlaxoSmithKline launched the Ellipta inhaler in 2021, equipped with a sensor for tracking inhaler usage and providing feedback on technique and disease management.
- Boehringer Ingelheim introduced the Respimat Smart digital inhaler in 2020, featuring a sensor for tracking inhaler usage and providing feedback on technique and disease management.
- AstraZeneca launched the Digihaler digital inhaler in 2020, utilizing sensors for tracking inhaler usage and offering feedback on technique and disease management.
Report Scope: The report covers historical data, revenue forecasts, company rankings, competitive landscape, growth factors, and trends. It includes segmentation by product type, application, and region. The global digital dose inhaler market is segmented into smart inhalers and sensor-based inhalers based on product type, with applications including asthma, COPD, and others. The regional scope covers North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, with key countries analyzed for market trends.
Explore Trending Reports:
Epoxy Coating Market-https://www.globenewswire.com/news-release/2020/08/04/2072717/0/en/Epoxy-Coating-Market-To-Reach-USD-48-40-Billion-By-2027-Reports-and-Data.html
Membrane Separation Technology Market-https://www.globenewswire.com/news-release/2020/09/21/2096755/0/en/Membrane-Separation-Technology-Market-To-Reach-USD-43-14-Billion-By-2027-Reports-and-Data.html
Squalene Market-https://www.globenewswire.com/news-release/2019/04/24/1809010/0/en/Squalene-Market-To-Reach-USD-309-7-Million-By-2026-Reports-And-Data.html
Request a customization of the report: https://www.reportsanddata.com/request-customization-form/6980
Thank you for reading our report. To know more about the customization or any query about the report contents, please connect with us and our team will ensure the report is tailored to meet your requirements.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
Browse Latest Blogs: https://www.reportsanddata.com/blogs
Browse Latest Press Release: https://www.reportsanddata.com/press-release
